High-Specificity Anti-Influenza A and B Antibodies for Rapid Test & FIA Development
The Sekbio Influenza A/B Antibody Pair consists of matched anti-Influenza A and anti-Influenza B monoclonal antibodies targeting the conserved nucleoprotein (NP) antigens — enabling simultaneous dual-type detection in a single lateral flow or FIA strip with type-specific result readout.
Influenza NP is the most abundant viral protein and highly conserved within each type (A or B), making anti-NP antibodies the preferred choice for broad-spectrum influenza rapid test development. The antibody pairs are validated for both colloidal gold LFA and fluorescent FIA platforms, supporting qualitative rapid tests and quantitative POCT readers respectively.
Influenza A and B NP antigens are highly conserved across strains and subtypes — anti-NP antibodies detect all H1N1, H3N2, and type B lineages (Victoria/Yamagata) without strain-specific gaps.
Clinical sensitivity exceeds 95% against culture/RT-PCR confirmed influenza specimens — meeting WHO and ECDC minimum performance requirements for influenza rapid diagnostic tests (RDTs).
Clinical specificity >98% confirmed against panel of common respiratory pathogens (RSV, adenovirus, parainfluenza, SARS-CoV-2) — minimizing false-positive results in co-circulating respiratory season.
Single test strip with separate type A and type B test lines enables simultaneous detection and differentiation — supporting antiviral treatment decisions (oseltamivir for both; baloxavir type-dependent).
15-minute result from NPS sample without laboratory equipment. Both colloidal gold (visual read) and fluorescent FIA (quantitative reader) formats supported from the same antibody pair.
Anti-influenza A and B antibody pairs available as separate OEM raw materials. Validated for nitrocellulose membrane coating and colloidal gold/fluorescent bead conjugation.
| Parameter | Influenza A | Influenza B |
|---|---|---|
| Clinical Sensitivity | >95% | >95% |
| Clinical Specificity | >98% | >98% |
| Reference Method | RT-PCR / Culture confirmed specimens | |
| Cross-Reactivity | No cross-reaction: RSV, adeno, parainfluenza, CoV | |
| Performance data from analytical and clinical validation studies. Full dataset available on request. | ||
| Influenza Strain / Subtype | Detected by Anti-NP | Clinical Relevance |
|---|---|---|
| Influenza A H1N1 (seasonal) | ✓ | Dominant seasonal strain globally |
| Influenza A H3N2 | ✓ | Second dominant seasonal A subtype |
| Influenza A H1N1pdm09 | ✓ | Pandemic origin, now seasonal |
| Influenza B Victoria lineage | ✓ (anti-B) | Predominant B lineage post-2020 |
| Influenza B Yamagata lineage | ✓ (anti-B) | Declared extinct 2024 — historical reference |
Anti-NP antibody pairs for colloidal gold LFA rapid influenza test kit development — providing type A/B differentiation in 15 minutes at the point of care.
Fluorescent bead-conjugated antibody pairs for quantitative FIA strip formats. Compatible with handheld fluorescent readers for emergency department and clinic use.
Rapid test development for influenza surveillance programs in high-risk settings (schools, nursing homes, airports). Dual A/B typing enables real-time subtype monitoring.
Anti-influenza A and B NP antibody pairs available as separate OEM components for rapid test manufacturers. Technical support for strip optimization and lot qualification.
Technical datasheets, performance data, and OEM supply details available on request.